Combining multiple meds into a single pill reduces cardiovascular deaths

Image Credit: Copilot Dall e-3 AI generated.

Taking a single pill that combines medications targeting cardiovascular disease-related conditions was shown long ago to lower the risk of death from such causes, including heart attacks and strokes. The concept of using such “polypills” to prevent and treat atherosclerotic cardiovascular disease was introduced nearly 25 years ago. Shortly thereafter, the strategy was the focus of a seminal modeling study that promoted polypills to reduce cardiovascular disease at the population level. Still, many years and a body of supportive research later, use of such pills remains low throughout the world.

Now, a new study from researchers at Washington University School of Medicine in St. Louis bolsters previous findings and provides additional evidence that polypills are beneficial in preventing heart attacks and strokes and reducing deaths among people with cardiovascular risk factors, including high blood pressure and high cholesterol. As a result of the study, the World Health Organization (WHO) has added such polypills to its most recent Model List of Essential Medicines. The list comprises medicines considered key to public health due to their importance in treating common diseases, as well as their safety, efficacy and cost-effectiveness.

‘Exhausted’ immune cells in healthy women could be target for breast cancer prevention

Photo Credit: Angiola Harry

Everyone has BRCA1 and BRCA2 genes, but mutations in these genes - which can be inherited - increase the risk of breast and ovarian cancer.

The study found that the immune cells in breast tissue of healthy women carrying BRCA1 or BRCA2 gene mutations show signs of malfunction known as ‘exhaustion’. This suggests that the immune cells can’t clear out damaged breast cells, which can eventually develop into breast cancer.

This is the first time that ‘exhausted’ immune cells have been reported in non-cancerous breast tissues at such scale - normally these cells are only found in late-stage tumors.

The results raise the possibility of using existing immunotherapy drugs as early intervention to prevent breast cancer developing, in carriers of BRCA1 and BRCA2 gene mutations.

The researchers have received a ‘Biology to Prevention Award’ from Cancer Research UK to trial this preventative approach in mice. If effective, this will pave the way to a pilot clinical trial in women carrying BRCA gene mutations.

“Our results suggest that in carriers of BRCA mutations, the immune system is failing to kill off damaged breast cells - which in turn seem to be working to keep these immune cells at bay,” said Professor Walid Khaled in the University of Cambridge’s Department of Pharmacology and Wellcome-MRC Cambridge Stem Cell Institute, senior author of the report.

Patients with delirium more likely to develop dementia

Professor Ruth Hubbard interacting with a patient.
Photo Credit: The University of Queensland

University of Queensland researchers have found older patients who experience delirium are three times more likely to develop dementia.

Professor Ruth Hubbard from UQ’s Centre for Health Services Research (CHSR) said the study also found that every episode of delirium increased the chance of developing dementia by 20 per cent.

“Delirium is an acute confusional state which particularly impacts older people and can have long term detrimental effects on patients,” Professor Hubbard said.

“Our study found that it is also strongly linked to dementia.”

The researchers analyzed a cohort of more than 110,000 patients from New South Wales hospitals over five years.

Lead author and CHSR research fellow, Dr Emily Gordon, said more than 55,000 patients who had experienced delirium were compared to patients who had not.

Liquid crystal nanoparticles supercharge antibiotics for cystic fibrosis

Image Credit: Copilot Dall E-3 AI generated

Cystic fibrosis is the most common, life-limiting genetic condition in Australia. It affects the lungs, digestive system, and reproductive system, producing excess mucus, infections, and blockages.

Now, thanks to a $500,000 grant from Brandon BioCatalyst's CUREator incubator, through their CSIRO-funded Minimizing Antimicrobial Resistance Stream, University of South Australia researchers are advancing the development of liquid crystal nanoparticle-formulated antibiotics to more accurately target and eliminate difficult-to-cure lung infections in people with cystic fibrosis.

Funded by the Medical Research Future Fund CUREator provides grant funding to support the development of Australian biomedical research and innovations.

The study will use a patent-protected platform technology, invented by UniSA’s Centre for Pharmaceutical Innovation to establish new therapies for cystic fibrosis sufferers. UniSA will also work with the Cystic Fibrosis Airways Research Group at the Women’s and Children’s Hospital to advance the platform.

Researchers a step closer to a cure for HIV

HIV, the AIDS virus (yellow), infecting a human cell
Image Credit: National Cancer Institute

A new study involving University of Bristol researchers has shown a virus-like particle (HLP) can effectively 'shock and kill' the latent HIV reservoir.

By 2030, the World Health Organization (WHO), the Global Fund and UNAIDS are hoping to end the human immunodeficiency virus (HIV) and AIDS epidemic. An international team of researchers led by Professor Eric Arts from the Schulich School of Medicine & Dentistry, Canada, and Dr Jamie Mann, Senior Lecturer at the University of Bristol, has brought us another step closer to meeting this goal, by finding an effective and affordable targeted treatment strategy for an HIV cure. 

In a first, the study published in Emerging Microbes and Infections demonstrated the team's patented therapeutic candidate. The HIV-virus-like-particle (HLP), is 100 times more effective than other candidate HIV cure therapeutics for people living with chronic HIV on combined antiretroviral therapy (cART). If successful in clinical trials, HLP could be used by millions of people living around the world to free them of HIV. This study was done using blood samples from people living with chronic HIV. 

HLPs are dead HIV particles hosting a comprehensive set of HIV proteins that increase immune responses without infecting a person. When compared with other potential cure approaches, HLP is an affordable biotherapeutic and can be administered by intramuscular injection – similar to the seasonal flu vaccine. 

New Study Reveals Who Was More Vulnerable to Post-COVID Syndrome in Early Phases of the Pandemic

Fatigue, malaise and difficulty breathing were associated with post-COVID syndrome, according to the new Nordic study.
Photo Credit: Kinga Howard

People with post-COVID syndrome (PCS) following the COVID-19 infection often suffer from intense fatigue and dyspnea. This is what emerges from a new Nordic study led by Umeå University and recently published in the BMJ Public Health journal. High blood pressure also appears to be a risk factor for PCS diagnosis, according to the study’s findings.

"These scientific results are an important step in better understanding PCS. By identifying key factors, we can improve diagnosis, adapt care and pave the way for research into more effective treatments," says Anne-Marie Fors Connolly, MD PhD, Assoc Prof, clinical researcher at Umeå University and the study's senior author.

The study analyzed data from over one million people in Sweden who tested positive for COVID-19 during the period from February 2020 to May 2021. Of these, 1.5 percent, just over 16,000 people, were diagnosed with PCS after the main COVID-19 infection. They were diagnosed in both outpatient and inpatient care, which provided large datasets for the researchers to examine the clinical footprint of PCS. The researchers conducted an in-depth study of PCS symptoms in individuals who required ongoing healthcare three months after the COVID-19 infection.

Blood analysis predicts sepsis and organ failure in children

Photo Credit: Edward Jenner

University of Queensland researchers have developed a method to predict if a child is likely to develop sepsis and go into organ failure.

Associate Professor Lachlan Coin from UQ’s Institute for Molecular Bioscience said sepsis was a life-threatening condition where a severe immune response to infection causes organ damage.

“Our research involved more than 900 critically ill children in the emergency departments and intensive care units of four Queensland hospitals,” Dr Coin said.

“Blood samples were taken from these patients at the acute stage of their infection, and we analyzed which genes were activated or deactivated.

“We were able to identify patterns of gene expression which could predict whether the child would develop organ failure within the next 24 hours, as well as whether the child had a bacterial or viral infection or a non-infectious inflammatory syndrome.”

Professor Luregn Schlapbach from UQ’s Child Health Research Centre said sepsis is best treated when recognized early, so the finding could help clinicians in the future.

CBD products don’t ease pain and are potentially harmful – new study finds

CBD oil may be popular for treating pain but taking it appears to be a waste of money
Photo Credit: Julia Teichmann

There is no evidence that CBD products reduce chronic pain, and taking them is a waste of money and potentially harmful to health, according to new research led by the University of Bath.

CBD (short for cannabidiol) is one of many chemicals found naturally in the cannabis plant. It’s a popular alternative treatment for pain and is readily available in shops and online in the form of oils, tinctures, vapes, topical creams, edibles (such as gummy bears) and soft drinks.

However, consumers would do well to steer clear of these products, according to the new study.

“CBD presents consumers with a big problem,” said Professor Chris Eccleston, who led the research from the Centre for Pain Research at Bath. “It’s touted as a cure for all pain but there’s a complete lack of quality evidence that it has any positive effects.”

He added: “It’s almost as if chronic pain patients don’t matter, and that we’re happy for people to trade on hope and despair.”

For their study, published this week in The Journal of Pain, the team – which included researchers from the Universities of Bath, Oxford and Alberta in Canada – examined research relevant to using CBD to treat pain and published in scientific journals up to late 2023.

Research offers hope for preventing post-COVID ‘brain fog’ by targeting brain’s blood vessels

Blood vessel endothelial cells (green) and basement membrane (red) in the brain.
Image Credit: Sarah Lutz

Among the many confounding symptoms in patients recovering from a COVID-19 infection are memory loss and difficulty learning. Yet little is known about the mechanisms of cognitive impairments like these, commonly called brain fog. 

In a new study, researchers at the University of Illinois Chicago have identified a mechanism that causes neurological problems in mice infected with SARS-CoV-2, the virus behind COVID-19. The researchers also found a treatment that helped prevent these changes. Sarah Lutz, assistant professor of anatomy and cell biology in the College of Medicine, led the research, which was published in the journal Brain.

The team focused on the blood-brain barrier, which plays a role in other neurological diseases, such as multiple sclerosis. Normally, this barrier protects the brain from potentially harmful cells or molecules circulating in the bloodstream. But the infected mice, researchers found, had leaky blood-brain barrier vessels and impaired memory or learning.

To understand why, the researchers looked at blood vessels from the brains of infected mice to see which genes were most altered. They found a significant decrease in a signaling pathway called Wnt/beta-catenin, which helps maintain the health of the blood-brain barrier and protects the brain from damage.

Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

Photo Credit: National Cancer Institute

A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only improved invasive-free survival in women with this type of early-stage breast cancer, but also improves distant disease-free survival and recurrence-free survival.

The results were published today in the New England Journal of Medicine and findings were presented last year at the American Society of Clinical Oncology Annual Meeting in Chicago.

“We found that adding ribociclib to the standard hormone therapy resulted in a relative reduction in the recurrence rate by as much as 25%,” said first author of the study Dr. Dennis Slamon, chair of hematology-oncology at the David Geffen School of Medicine at UCLA and director of clinical and translational research at the UCLA Health Jonsson Comprehensive Cancer Center. “And that’s huge for this the group of patients, who make up 70% to 75% of breast cancer cases.”

Many patients with this type of breast cancer are treated with surgery, and in some cases with radiation and chemotherapy, followed by endocrine therapy for up to 10 years to help reduce their risk of recurrence.

A protein found in human sweat may protect against Lyme disease

Human sweat contains a protein that may protect against Lyme disease, according to a study from MIT and the University of Helsinki. About one-third of the population carries a genetic variant of this protein that is associated with Lyme disease in genome-wide association studies.
Photo Credit: Erik Karits

Lyme disease, a bacterial infection transmitted by ticks, affects nearly half a million people in the United States every year. In most cases, antibiotics effectively clear the infection, but for some patients, symptoms linger for months or years.

Researchers at MIT and the University of Helsinki have now discovered that human sweat contains a protein that can protect against Lyme disease. They also found that about one-third of the population carries a genetic variant of this protein that is associated with Lyme disease in genome-wide association studies.

It’s unknown exactly how the protein inhibits the growth of the bacteria that cause Lyme disease, but the researchers hope to harness the protein’s protective abilities to create skin creams that could help prevent the disease, or to treat infections that don’t respond to antibiotics.

“This protein may provide some protection from Lyme disease, and we think there are real implications here for a preventative and possibly a therapeutic based on this protein,” says Michal Caspi Tal, a principal research scientist in MIT’s Department of Biological Engineering and one of the senior authors of the new study.

Hanna Ollila, a senior researcher at the Institute for Molecular Medicine at the University of Helsinki and a researcher at the Broad Institute of MIT and Harvard, is also a senior author of the paper, which appears today in Nature Communications. The paper’s lead author is Satu Strausz, a postdoc at the Institute for Molecular Medicine at the University of Helsinki.

Fighting heart attack down to the smallest vessels

Graphical Abstract of drug infusion for MVO treatment via regular vs. balloon catheter.
Image Credit: © ARTORG Center

Researchers in Bern have co-developed and tested a new method to combat the blockage of tiny coronary arteries after a heart attack. The new approach, born from a cooperation of engineers, clinicians, and industry, offers a treatment option to prevent the death of heart tissue after a heart attack, responsible for poor long-term patient health.

In myocardial infarction (heart attack), the supply of the heart muscle with oxygen and nutrients is blocked by an obstruction of a major coronary artery. Even after recanalization of this artery via stent, secondary obstructions in the cardiac microcirculation (Microvascular Obstruction, MVO) occur in 40-60% of all patients. This can lead to the death of heart tissue, with a negative impact on the long-term cardiovascular health of patients. Around 200,000 people are affected by this in Switzerland every year.

New strategy to facilitate muscle regeneration after injury

From left to right, Ginés Viscor, Joan Ramon Torrella and Garoa Santocildes.
Photo Credit: Courtesy of University of Barcelona

Muscle injuries are common in the active population, and they cause the majority of player leaves in the world of sport. Depending on the severity, recovery of muscle function is quite slow and may require surgery, medication and rehabilitation. Now, a study led by the University of Barcelona reveals a strategy to improve and accelerate recovery from muscle injuries that has potential application in the sports and health sector in general.

This is the first study to provide scientific evidence for faster and more effective recovery from muscle injuries through intermittent exposure to low oxygen availability (hypoxia) in a low-barometric pressure (hypobaric) chamber that simulates high-altitude geographic conditions.

The new approach is important for the recovery of athletes — especially in the competitive elite — but also to mitigate the socio-economic impact of the loss of work productivity caused by these injuries on the active population.

The study, carried out with animal models, has been published in the Journal of Physiology. The authors of the study are the experts Garoa Santoildes, Teresa Pagès, Joan Ramon Torrella and Ginés Viscor, from the Department of Cell Biology, Physiology and Immunology of the UB’s Faculty of Biology.

Attacking metastatic prostate cancer early with combination treatment approach improves outcomes in preliminary study

Photo Credit: Accuray

A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body.

In the small study, researchers found that 50% of the patients who were treated with the combination therapy had no signs of the cancer and remained free of recurrence six months after their treatment, with less than a quarter experiencing severe side effects from the treatment. 

“In contrast, without this combined treatment approach, we would expect approximately 1% of patients to have no evidence of disease at the six-month stage,” said Dr. Amar Kishan, professor of radiation oncology at the David Geffen School of Medicine at UCLA and senior author of the study. “These results suggest a substantial improvement and strongly suggest there can be a meaningful impact —namely, delaying the need for hormonal therapy and thus without the significant side effects of it— by attacking metastatic prostate cancer early.”

The results were published in the journal of European Urology.

Nearly all men who are diagnosed with metastatic hormone-sensitive prostate cancer are treated with androgen deprivation therapy, a type of hormonal therapy that aims to lower the levels of male hormones called androgens that can stimulate the growth of prostate cancer cells. 

Even small amounts of licorice raise blood pressure

Researchers have studied how licorice affects blood pressure, among other things.
Photo Credit: Marion Wellmann

It is known that large amounts of licorice cause high blood pressure. A study by researchers at Linköping University now shows that even small amounts of licorice raise blood pressure. The individuals who react most strongly also show signs of strain on the heart.

Licorice is produced from the root of plants of the Glycyrrhiza species and has long been used as an herbal remedy and flavoring. However, it is known that eating licorice can also raise blood pressure. This is mainly due to a substance called glycyrrhizic acid that affects the body’s fluid balance through effects on an enzyme in the kidney. High blood pressure, in turn, increases the risk of cardiovascular disease.

Both the European Union and the World Health Organization have concluded that 100 mg of glycyrrhizic acid per day is probably safe to eat for most individuals. But some people eat more licorice than that. The Swedish Food Agency has estimated that 5 per cent of Swedes have an intake higher than this level.

Keeping score: novel method might help differentiate 2 serious skin diseases

Close-up of skin symptoms   
A scoring system has been developed to help distinguish between the two diseases. Left: generalized pustular psoriasis (GPP). Right: acute generalized exanthematous pustulosis (AGEP).   
Image Credit: Osaka Metropolitan Universit

Two rare skin conditions with similar symptoms can be mistaken for each other, so a scoring system has been formulated to aid physicians in distinguishing two diseases

Your skin becomes red and spots filled with pus appear, so you visit a dermatologist. When these symptoms spread to the skin throughout the body, it is difficult for the physician to distinguish whether it is generalized pustular psoriasis (GPP) or acute generalized exanthematous pustulosis (AGEP), as both have similar symptoms. The two diseases run different courses and require different treatments. Without proper treatment, the symptoms can worsen severely and cause complications, so it is essential to distinguish between them.

Researchers from Osaka Metropolitan University and the Mayo Clinic in the United States have developed a scoring system as a novel tool to distinguish between the two diseases. Led by Dr. Mika Yamanaka-Takaichi and Professor Daisuke Tsuruta, both from the Department of Dermatology at OMU’s Graduate School of Medicine, and Professor Afsaneh Alavi from the Department of Dermatology at the Mayo Clinic in Rochester, Minnesota, the team studied data on clinical symptoms and laboratory findings of the diseases to create the system.

It's in the Blood: Donor Diets Can Trigger Allergic Reactions in Blood Recipients

Photo Credit: Aman Chaturvedi

Blood transfusions are often life-saving procedures in various medical settings. They are required not only after severe blood loss due to surgery or trauma but also as standard treatment for certain blood disorders like anemia and sickle cell disease. However, blood transfusions can have serious side effects, with allergic transfusion reactions (ATRs) being particularly prevalent among children. Although scientists believe ATRs are caused by immunoglobulin E (IgE)-mediated type 1 allergy (or “immediate hypersensitivity”), the responsible allergens are not always known.

Against this backdrop, a research team composed of Dr. Ryu Yanagisawa of Shinshu University Hospital, Japan, alongside Dr. Minoru Tozuka and Dr. Yasunori Ito from Nagano Children's Hospital, Japan, set out to find more answers. In their latest study, published online in the journal Allergy, the researchers focused their attention on what might have appeared to be an unlikely suspect. Dr. Yanagisawa, wo led the study at the University’s Division of Blood Transfusion, explains: “In our previous study, we found that pediatric patients with food allergies were characteristically more prone to ATRs. Considering that food allergies are also more prevalent in children, we decided to investigate whether the food the donor ate before giving blood could be associated with the development of ATRs in children with food allergies.”

Maternal obesity may promote liver cancer

Obese mice pass on an altered microbiome to their offspring, which has an impact on liver health in adulthood and increases the risk of liver cancer. Normalising the intestinal microbiome reduces the risk of cancer. Specific families of bacteria are linked to tumour burden and liver inflammation.
Image Credit: Toso, Moeckli et al. 2024
CC-by-nc-nd

A team from the UNIGE and the HUG has revealed the role of the microbiota in the increased risk of developing liver disease in the offspring of mothers suffering from obesity.

Obesity, which could reach 50% of the population in certain developed countries by 2030, is a major public health concern. It not only affects the health of those who suffer from it, but could also have serious consequences for their offspring. Scientists at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the impact of maternal obesity on the risk of developing liver disease and liver cancer. Using an animal model, the team discovered that this risk was indeed much higher in the offspring of mothers suffering from obesity. One of the main causes was the transmission of a disturbed intestinal microbiota from the mother, resulting in a chronic liver disease whose effects became apparent in adulthood. These results, which have yet to be confirmed in humans, are a warning signal and a call for action to limit the deleterious effect of obesity on children. This research is published in the journal JHEP Reports.

Researchers identify distinct sleep types and their impact on long-term health

Photo Credit: Sam Moghadam Khamseh

Poor sleep habits are strongly associated with long-term chronic health conditions, according to decades of research. To better understand this relationship, a team led by researchers in Penn State’s College of Health and Human Development identified four distinct patterns that characterize how most people sleep. These patterns are also predictive of long-term health, the researchers said.

Soomi Lee, associate professor of human development and family studies at Penn State, led a team in identifying these sleep patterns and their correlation to overall health. Their results were published in Psychosomatic Medicine.

Using a national sample of adults from the Midlife in the United States study, the team gathered data on approximately 3,700 participants’ sleep habits and their chronic health conditions across two time points 10 years apart. The data included self-reported sleep habits, including sleep regularity and duration, perceived sleep satisfaction and daytime alertness, as well as the number and type of chronic conditions.

Shape-shifting ultrasound stickers detect post-surgical complications

Three variations of the soft, flexible ultrasound sticker device displayed on a finger.
Photo Credit: Jiaqi Liu / Northwestern University

Researchers led by Northwestern University and Washington University School of Medicine in St. Louis have developed a new, first-of-its-kind sticker that enables clinicians to monitor the health of patients’ organs and deep tissues with a simple ultrasound device.

When attached to an organ, the soft, tiny sticker changes in shape in response to the body’s changing pH levels, which can serve as an early warning sign for post-surgery complications such as anastomotic leaks. Clinicians then can view these shape changes in real time through ultrasound imaging.

Currently, no existing methods can reliably and non-invasively detect anastomotic leaks — a life-threatening condition that occurs when gastrointestinal fluids escape the digestive system. By revealing the leakage of these fluids with high sensitivity and high specificity, the non-invasive sticker can enable earlier interventions than previously possible. Then, when the patient has fully recovered, the biocompatible, bioresorbable sticker simply dissolves away — bypassing the need for surgical extraction.

The study is published in the journal Science. The paper outlines evaluations across small and large animal models to validate three different types of stickers made of hydrogel materials tailored for the ability to detect anastomotic leaks from the stomach, the small intestine and the pancreas.